Literature for peptidase S01.017: kallikrein-related peptidase 5

(References are filtered for relevance to Inhibitor. To remove the filter click here. See explanation.)

2019
1. Di Paolo,C.T., Filippou,P.S., Yu,Y., Poda,G., Diamandis,E.P. and Prassas,I.
   Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses
   Clin Chem Lab Med57, 1737-1743. PubMed  Europe PubMed DOI  I
2. Walker,A.L., Denis,A., Bingham,R.P., Boulliot,A., Edgar,E.V., Ferrie,A., Holmes,D.S., Laroze,A., Liddle,J., Fouchet,M.H., Moquette,A., Nassau,P., Pearce,A.C., Polyakova,O., Smith,K.J., Thomas,P., Thorpe,J.H., Trottet,L., Wang,Y. and Hovnanian,A.
   Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors
   Bioorg Med Chem Lett29, 126675-126675. PubMed  Europe PubMed DOI  I
3. Walker,A.L., Bingham,R.P., Edgar,E.V., Ferrie,A., Holmes,D.S., Liddle,J., Polyakova,O., Rella,M., Smith,K.J., Thorpe,J.H., Wang,Y., White,G.V., Young,R.J. and Hovnanian,A.
   Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome
   Bioorg Med Chem Lett29, 1454-1458. PubMed  Europe PubMed DOI  I
4. White,G.V., Edgar,E.V., Holmes,D.S., Lewell,X.Q., Liddle,J., Polyakova,O., Smith,K.J., Thorpe,J.H., Walker,A.L., Wang,Y., Young,R.J. and Hovnanian,A.
   Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome
   Bioorg Med Chem Lett29, 821-825. PubMed  Europe PubMed DOI  M  I
2017
5. Fang,X., Bagui,S. and Bagui,S.
   Improving virtual screening predictive accuracy of human kallikrein 5 inhibitors using machine learning models
   Comput Biol Chem69, 110-119. PubMed  Europe PubMed DOI  I
6. Matsubara,Y., Matsumoto,T., Koseki,J., Kaneko,A., Aiba,S. and Yamasaki,K.
   Inhibition of human kallikrein 5 protease by triterpenoids from natural sources
   Molecules22, PubMed  Europe PubMed DOI  I
2016
7. Hoelz,L.V., Zorzanelli,B.C., Azevedo,P.H., Passos,S.G., de Souza,L.R., Zani,M., Pinheiro,S., Puzer,L., Dias,L.R. and Muri,E.M.
   Synthesis, biological evaluation and molecular modeling of pseudo-peptides based statine as inhibitors for human tissue kallikrein 5
   Eur J Med Chem112, 39-47. PubMed  Europe PubMed DOI  I
2015
8. Severino,B., Fiorino,F., Corvino,A., Caliendo,G., Santagada,V., Assis,D.M., Oliveira,J.R., Juliano,L., Manganelli,S., Benfenati,E., Frecentese,F., Perissutti,E. and Juliano,M.A.
   Synthesis, biological evaluation, and docking studies of PAR2-AP-derived pseudopeptides as inhibitors of kallikrein 5 and 6
   Biol Chem396, 45-52. PubMed  Europe PubMed DOI  I
9. Tan,X., Soualmia,F., Furio,L., Renard,J.F., Kempen,I., Qin,L., Pagano,M., Pirotte,B., El Amri,C., Hovnanian,A. and Reboud-Ravaux,M.
   Toward the first class of suicide inhibitors of kallikreins involved in skin diseases
   J Med Chem58, 598-612. PubMed  Europe PubMed DOI  I
2013
10. Tan,X., Furio,L., Reboud-Ravaux,M., Villoutreix,B.O., Hovnanian,A. and El Amri,C.
    1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases
    Bioorg Med Chem Lett23, 4547-4551. PubMed  Europe PubMed DOI  I
2011
11. Teixeira,T.S., Freitas,R.F., Abrahao,O., Jr., Devienne,K.F., de Souza,L.R., Blaber,S.I., Blaber,M., Kondo,M.Y., Juliano,M.A., Juliano,L. and Puzer,L.
    Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7
    Bioorg Med Chem Lett21, 6112-6115. PubMed  Europe PubMed DOI  I